Business Wire

Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System

Share

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today unveiled the company’s second Super Bowl commercial, which announces the US launch of its next-generation Dexcom G7 CGM System. The ad, which will run during the second quarter of Super Bowl LVII on Feb. 12, 2023, stars multi-platinum recording artist, songwriter, actor and philanthropist, Nick Jonas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005121/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Nick Jonas on set during production of Dexcom's 2023 Super Bowl commercial launching its new Dexcom G7 CGM System. (Photo: Business Wire)

“Dexcom CGM has changed my life and revolutionized the way I take care of my health,” said Jonas. “People with diabetes – whether Type 1 or Type 2 – should have the best technology available to manage their disease, and with Dexcom G7, they’ll have it. I’m excited for the opportunity to share this new device with the world and to raise awareness around the magic of CGM. Raising awareness of this technology for the millions of Americans who need it is one key step toward ensuring people with diabetes have the best technology available to live beyond their diagnosis.”

Dexcom G7 is the most accurate,1 easy to use CGM available – it’s not magic, it just feels that way.

In the Super Bowl spot, Jonas, who was diagnosed with Type 1 diabetes at the age of 13, uses a magician’s sleight of hand and some CGI wizardry to reveal the new CGM system to the world.

With Dexcom G7, the #1 recommended CGM brand7,8 now offers the most accurate1 and simple way to help people gain greater control of their diabetes, so they can manage the disease with more confidence. Its low-profile, all-in-one wearable warms up faster than any other CGM on the market, sending real-time glucose readings automatically to a compatible smart deviceor receiver, no painful fingersticks* or burdensome scanning required. With an overall MARD of 8.2%, Dexcom G7 is the most accurate CGM on the market,1 building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range.2-6 Dexcom G7 is also the only integrated CGM system trusted for use during pregnancy, delivering better peace of mind to pregnant patients managing Type 1, Type 2 and gestational diabetes.

Increasing CGM awareness is critical to help millions of people with diabetes start using the latest diabetes management technology to improve their health and quality of life.

  • More than 4.8 million Americans with diabetes who use insulin are expected to watch Super Bowl LVII1,9
  • Despite CGM being established as the standard of care in diabetes management, about 3.3 million of those viewers don’t currently use CGM to manage their diabetes1
  • Of those 3.3 million people watching on Sunday not using CGM, 70%, or more than 2.3 million, have coverage for CGM or are expected to have coverage for CGM by the end of 2023 through private insurance, Medicare or Medicaid1,10
  • Dexcom is the number one covered and most reimbursed CGM on the market10 with a third of patients with commercial coverage paying $0 out of pocket and the majority paying less than $40 per month§,11

“At Dexcom, we are in the business of providing information that can help people with diabetes better manage their disease. With so many people still unaware of CGM and how it can benefit them, we thought the best way to get the word out was to partner once again with one of the biggest stars on the biggest stage,” said Kevin Sayer, chairman, president and CEO of Dexcom. “Nick Jonas and the Super Bowl is a magical combination to encourage millions of Americans with diabetes to get started with Dexcom G7 and begin their journey toward better controlled diabetes and improved health.”

Diabetes is a serious problem that has reached epidemic proportions with no signs of slowing down. Today, the global burden of diabetes reaches 537 million people and costs nearly $1 trillion in diabetes-related health expenditures.12 What’s more, the rate of young people with diabetes in the US alone is projected to surge 146% by 2060.13 Now more than ever, it is essential to raise awareness for life-changing CGM technology that has revolutionized diabetes management.

The Super Bowl ad is at the center of a broader awareness campaign that aims to highlight the “magic moments” people with diabetes can experience with a little help from their Dexcom CGM. The campaign asks the diabetes community to share the personal “magic moments” they are most proud of on social media to show the world diabetes doesn’t have to hold anyone back. A group of seven Dexcom Warriors were invited to the Super Bowl set for a behind-the-scenes look at the spot and to share their inspiring stories with Jonas, including Mireya Martinez, a Texas-based pastor living with Type 2 diabetes.

“Diabetes is a relentless disease and managing it properly can sometimes feel impossible,” said Martinez. “Being surrounded by so many other people with diabetes on set who understand what it’s like to live with this disease was an inspiring experience. It is extremely rewarding to be part of this Super Bowl campaign raising awareness for CGM and helping people with diabetes feel understood and represented. I am so excited for Dexcom G7 to launch and for millions of people to experience the magic of CGM for themselves.”

To facilitate immediate access to Dexcom G7 for as many users as possible, Dexcom will have accessible cash pay options in place at launch as the company transitions coverage availability for the new system.

Visit Dexcom.com/Magic today to get started with Dexcom G7.

About DexCom, Inc.

Dexcom, Inc. empowers people to take control of health through innovative continuous glucose monitoring systems. Headquartered in San Diego, Calif., Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom, visit dexcom.com/about-dexcom.

*Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. To view a list of compatible smart devices, visit dexcom.com/compatibility . §Refers to estimated out-of-pocket cost for eligible commercially insured patients from the Dexcom CGM sensor when claims are adjudicated as a pharmacy benefit, and includes benefits and offerings through available Dexcom programs, such as the voucher program. Actual cost may vary and is subject to individual insurance coverage.

1 Dexcom, data on file, 2022. 2 Welsh JB, et al. J Diabetes Sci Technol. 2022:19322968221099879. 3 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39. 4 Beck RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 d&A US Q1 2021 Diabetes Connections Patient Panel Report.2021;69-72. 8 Seagrove HCP Survey Q1 2021. 2021;65. 9 “Super Bowl LVI total viewing audience estimated at over 208 million.” NFL.com. Accessed January 26, 2023. https://www.nfl.com/news/super-bowl-lvi-total-viewing-audience-estimated-at-over-208-million. 10 Managed Markets Insights & Technology, LLC. MMIT Analytics, June 2022. 11 IQVIA, February 2022. 12 “International Diabetes Federation seeks input into survey on access to diabetes education.” FDA World Dental Federation. Accessed January 26, 2023. 13 Tönnies T, et al. Diabetes Care 2023;46(2):313–320.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Announces First-Quarter 2023 Results Conference Call20.3.2023 20:00:00 EET | Press release

SLB (NYSE: SLB) will hold a conference call on April 21, 2023 to discuss the results for the first quarter ending March 31, 2023. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 8858313. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 21, 2023, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402) 970-0847 outside of North

Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼in the European Economic Area, the United Kingdom, Australia and Brazil20.3.2023 19:28:00 EET | Press release

Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil. “Theramex has again shown its commitment to women and the care and good management of bone health, by adding this important product to our Osteoporosis franchise. We are delighted to be entering into this partnership with Radius, building on our expanding portfolio and aligning missions to reduce fracture risks for many postmenopausal women suffering from osteoporosis.” - Rob Stewart, CEO of Theramex “We are thrilled to have Theramex bring abaloparatide to postmenopausal women in Europe who coul

New Stilla Ruby Chip and naica® system 21 CFR Part 11 compliance enable full automation of digital PCR testing for clinically-oriented applications20.3.2023 18:48:00 EET | Press release

Stilla Technologies, the multiplex digital PCR company, has recently introduced the Ruby Chip, the industry’s first ‘load-and-go’ consumable for digital PCR, optimized for its naica® system. The naica® system, which now supports 21 CFR Part 11 regulatory compliance, is part of a fully-automated sample-to-results workflow – the first of its kind for digital PCR. This platform serves the growing throughput and regulatory requirements of many clinically-oriented applications, such as in cell and gene therapy development and quality control or for liquid biopsy applications for the detection of circulating tumor DNA (ctDNA). With adjustable throughput of up to 96 samples processing capability in under three hours, the Ruby Chip is designed with standard SBS plate spacing compatible with multichannel pipettes for manual loading and can be easily integrated with common liquid handling robots. A key feature of the Ruby Chip is that it comes ready-to-use and preloaded with sealed chambers, ena

FlexTrade Hires Senior Sell-Side OMS Specialist to Drive Growth in EMEA Region20.3.2023 17:30:00 EET | Press release

FlexTrade Systems (@FlexTrade), a global leader in multi-asset order and execution management systems, announces the appointment of Rajiv Shah as Head of Sales in EMEA for its sell-side OEMS, FlexOMS. FlexOMS, the flagship OMS platform within FlexTrade's suite of sell-side solutions, is designed to boost trading efficiency by simplifying the complexities of today's trading workflows. The open-architecture trading solution supports high-touch and low-touch businesses by providing a unified multi-asset platform across cash, program trading, futures & options, ETF, swaps, fixed income, and foreign exchange workflows. In this newly created role, Rajiv will drive FlexTrade's business strategy and growth of the solutions to trading desks within EMEA. Rajiv brings over 30 years of experience in financial technology with a proven track record in designing and executing sales and business growth strategies across the front and middle-office trading space within enterprise-grade software firms.

LambdaTest improves its Selenium automation testing experience with the addition of its AI-powered integrated test intelligence20.3.2023 17:30:00 EET | Press release

LambdaTest, an intelligent omnichannel digital experience testing cloud platform, has announced the addition of advanced AI-powered test intelligence features to its Selenium testing cloud offering. With this latest development, LambdaTest will now enable enterprises with deeper insights into their test execution process and help them better streamline their quality assurance process. LambdaTest has been constantly working on enhancing its Selenium automation testing cloud and the test intelligence feature is the latest addition to the list. Over the last quarter, LambdaTest has added features like support for all Selenium 4 versions, including support for BiDi protocol, enhanced low-latency live streaming of test execution for faster test feedback, and the ability to group tests by tags for better manageability. Just last month, LambdaTest added Selenium tracing that allows users to visualize each command flow and each test error along with its telemetry data. All these features combi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom